Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

26.1%

6 terminated/withdrawn out of 23 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

4%

1 trials in Phase 3/4

Results Transparency

44%

4 of 9 completed trials have results

Key Signals

4 recruiting4 with results

Enrollment Performance

Analytics

Phase 2
10(45.5%)
Phase 1
10(45.5%)
Phase 3
1(4.5%)
Early Phase 1
1(4.5%)
22Total
Phase 2(10)
Phase 1(10)
Phase 3(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT06225310Phase 1Recruiting

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Role: lead

NCT06115135Phase 2Recruiting

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Role: lead

NCT06209606Early Phase 1Recruiting

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Role: lead

NCT02188368Phase 2Terminated

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Role: lead

NCT03110822Phase 1Recruiting

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Role: lead

NCT02294357Phase 2Terminated

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Role: lead

NCT02206425Phase 1Completed

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Role: lead

NCT04519476Phase 1Unknown

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Role: lead

NCT03733691Phase 2Terminated

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Role: lead

NCT03104270Phase 2Terminated

Combination Study for High Risk Multiple Myeloma Patients

Role: lead

NCT02285101Phase 1Completed

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

Role: collaborator

NCT01365559Phase 1Completed

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Role: lead

NCT01697839Completed

Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients

Role: lead

NCT01792102Phase 1Unknown

Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma

Role: lead

NCT01695330Phase 2Terminated

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

Role: lead

NCT01541332Phase 1Unknown

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Role: lead

NCT01160484Phase 2Completed

Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

Role: lead

NCT01160380Phase 3Completed

A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma

Role: lead

NCT00743288Phase 1Completed

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Role: lead

NCT00742404Phase 2Unknown

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Role: lead